Unlock Your Potential with Xentria Meitheal The Collaboration Hub

... Meitheal Pharmaceuticals, Inc.（以下简称“Meitheal”“被许可方”）拟与Xentria签署《许可、开发与商业化协议》（以下简称《许可协议》），Xentria授予 ... Tom is the founding CEO of Meitheal since its inception in 2017. In addition, Tom is also the founding President of Xentria, Inc. Immunology. Study Phase : Phase I/ Phase II. Recipient : Xentria. Deal Size : $680.0 million. Deal Type : Licensing Agreement. DEALS_DEV arrow-down · Xentria ... Xentria Inc./Meitheal. Pharmaceuticals Inc. In clinical trials. Molecule. Innovator product (company) Biosimilars. Company. Status. Omalizumab. Xolair® ( ... 健友股份(603707)6月27日晚间公告，公司全资子公司香港健友（被许可方代表）及香港健友控股子公司Meitheal（被许可方）拟与Xentria签署许可协议，Xentria授予被许可方 ... 健友股份(603707)6月27日晚间公告，公司全资子公司香港健友（被许可方代表）及香港健友控股子公司Meitheal（被许可方）拟与Xentria签署许可协议，Xentria授予被许可方 ... Meitheal Pharmaceuticals, Chicago, IL, Generics. Add'l Locations Novian Health ... Xentria, Chicago, IL, Biologics & Biosimilars, Monoclonal Antibody. Add'l ... Perkins Coie Advises Xentria in Multi-Year Licensing Agreement with Meitheal to Market Xentria's Novel Biologic to Treat Pulmonary Sarcoidosis · Home ... Tom Shea is the founding President of Xentria and the founding CEO of Meitheal Pharmaceutical, Inc. 健友股份(603707)6月27日晚间公告，公司全资子公司香港健友（被许可方代表）及香港健友控股子公司Meitheal（被许可方）拟与Xentria签署许可协议，Xentria授予被许可方 ...